Author:
Gupta A.,Love S.,Schuh A.,Shanyinde M.,Larkin J.M.,Plummer R.,Nathan P.D.,Danson S.,Ottensmeier C.H.,Lorigan P.,Collins L.,Wise A.,Asher R.,Lisle R.,Middleton M.R.
Funder
AstraZeneca
UK National Cancer Research Network
University of Oxford
NIHR
Royal Marsden and Institute of Cancer Research Biomedical Research Centre
Newcastle Experimental Cancer Medicine Centre
Sheffield ECMC
Sheffield CR-UK/YCR Cancer Research Centre
Biomedical Research Centre
Oxford ECMC
Reference21 articles.
1. International Agency for Research on Cancer. GLOBOCON 2008; http://globocan.iarc.fr/ 31 March 2013, date last accessed
2. Treatment of metastatic melanoma: an overview;Bhatia;Oncology (Williston Park),2009
3. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med,2012
4. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations;Flaherty;N Engl J Med,2012
5. Nivolumab plus ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2013
Cited by
60 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献